Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

BACKGROUND: Antibodies targeting the programmed death‐ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) checkpoint may cause adverse events (AEs) that are linked to the mechanism of action of this therapeutic class and unique from those observed with conventional chemotherapy. METHODS: Patient...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer
Main Authors: Kelly, Karen, Infante, Jeffrey R., Taylor, Matthew H., Patel, Manish R., Wong, Deborah J., Iannotti, Nicholas, Mehnert, Janice M., Loos, Anja H., Koch, Helga, Speit, Isabell, Gulley, James L.
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2018
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947549/
https://ncbi.nlm.nih.gov/pubmed/29469949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31293
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍